About
About Beijing Centergate Technologies (holding) Co., Ltd
Beijing Centergate Technologies (holding) Co., Ltd. engages in the production and sale of topical reagents, tablets, injections in China. The company offers Anemarrhena saponin BII and capsules for vascular dementia treatment; Naltrexone Hydrochloride tablets and injections to block the pharmacological effects of exogenous opioids; Acetaminophen and oxycodone tablets and injections for the treatment of moderate to severe pain; tramadol hydrochloride tablets and injections to treat pain in adults; aprolol hydrochloride for the treatment of hypertension, angina pectoris, tachycardia-induced arrhythmia, and tremor; buspirone hydrochloride tablets to treat various anxiety disorders; oxycodone hydrochloride extended-release tablets; and Ambroxol hydrochloride injection for the treatment of acute exacerbations of chronic bronchitis, wheezing bronchitis, and bronchial asthma. It also provides Febuxostat tablets for the treatment of hyperuricemia; Bromhexine Hydrochloride injection to treat asthma, bronchiectasis, and silicosis; Metoprolol succinate raw material; Bisoprolol Amlodipine tablets for hypertension; Sitagliptin/Metformin tablets are used for type 2 diabetes patients; Bisoprolol fumarate tablets for the treatment of hypertension, coronary, and artery diseases; and Tropanestone mesylate injection for the treatment of nausea and vomiting. In addition, the company offers Sildenafil lozenges, Benzyl nonyl hydrochloride tablets, Oxycodone Hydrochloride injection, Bifonazole cream, Huperzine A tablets, Wujia Biochemical capsules, Lactobacillus tablets, Tramadol acetaminophen tablets, Tramadol hydrochloride raw material, Clindamycin phosphate to treat bacterial vaginosis, Piracetam injection, Acanthopanax senticosus, Benidipine Hydrochloride for the treatment of hypertension and angina pectoris, Glipizide Dispersible tablets, and Compound Pancreatic Enzyme powders. Beijing Centergate Technologies (holding) Co., Ltd. was founded in 1999 and is based in Beijing, China.
Visit company website
5 years, 5 months ago
Beijing Centergate Technologies (holding) Co., Ltd is currently in a long term downtrend where the price is trading 5.6% below its 200 day moving average.
From a valuation standpoint, the stock is 62.6% cheaper than other stocks from the Real Estate sector with a price to sales ratio of 2.8.
Beijing Centergate Technologies (holding) Co., Ltd's total revenue sank by 7.6% to $479M since the same quarter in the previous year.
Its net income has dropped by 72.9% to $10M since the same quarter in the previous year.
Finally, its free cash flow fell by 22.9% to $-79M since the same quarter in the previous year.
Based on the above factors, Beijing Centergate Technologies (holding) Co., Ltd gets an overall score of 1/5.